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Glioblastoma multiforme (GBM) is the most common and malig-
nant primary brain tumour (Chamberlain and Kormanik, 1998).
Standard treatment for the initial treatment of these tumours is
surgical resection and postoperative radiation. A meta-analysis of
randomized clinical trials reports a modest survival advantage
with adjuvant chemotherapy (Fine et al, 1993). However, a recent
Medical Research Council randomized trial of 674 patients failed
to show a survival benefit of nitrosourea-based adjuvant
chemotherapy (Brada et al, 1998). Regardless of initial treatment,
most patients relapse (Feun et al, 1994). Single-agent or combina-
tion salvage chemotherapy regimens for recurrent high-grade
glioma remain palliative; median survival is 6 to 8 months, and
few patients survive more than 2 years (Forsyth, 1996;
Chamberlain and Kormarik 1998).
Temozolomide (TMZ) is a new orally administered, second-
generation imidazotetrazine prodrug with essentially 100% oral
bioavailability (Newlands et al, 1992). Preclinically, TMZ demon-
strated broad spectrum, schedule dependent, antitumour activity
with relatively little toxicity. TMZ spontaneously converts to the
active alkylating agent 5-(3-methyltriazen-1-yl) imidazole-4-
carboximide under physiologic conditions (Stevens et al, 1987;
Tsang et al, 1990) with extensive tissue distribution, including
penetration of the blood–brain barrier and the cerebrospinal fluid
(Patel et al, 1995; Brock et al, 1996, 1997). In phase I and II clin-
ical studies, TMZ was well tolerated with a favourable toxicity
profile, with easily managed noncumulative myelotoxicity. TMZ
has notable antitumour activity against recurrent GBM, recurrent
anaplastic astrocytoma, and advanced malignant melanoma, and
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Summary A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating
agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine
progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary
objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day
(prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for
28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ
was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison).
Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P =
0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease
progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most
adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign
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al, 1993; Bleehen et al, 1995; Bower et al, 1997).
This multicentre phase II study in patients with GBM at first
relapse was prompted by the activity of TMZ in recurrent or
progressive high-grade glioma and the need for new single-agent
treatments with improved efficacy, safety and health-related
quality of life (HRQL). The primary objectives were to evaluate
the progression-free survival (PFS) at 6 months and safety of
TMZ and the reference agent, procarbazine (PCB). PCB is one of
the few orally administered therapeutic options available to
patients with high-grade gliomas, particularly those who fail radi-
ation and nitrosourea therapy (Kumar et al, 1974; Rodriguez et al,
1989; Newton et al, 1990). The secondary objectives were to
evaluate the effect of TMZ on overall survival, HRQL and
response rate.
PATIENTS AND METHODS
Patients
Eligible patients were ≥ 18 years old, had histologically proven
supratentorial GBM or gliosarcoma and unequivocal evidence of
tumour recurrence or progression at first relapse by gadolinium
magnetic resonance imaging (Gd-MRI) or by contrast-enhanced
computerized tomography (CT) scanning after radiation therapy
for initial disease. Patients could have had one course of
chemotherapy that must have contained a nitrosourea and were
required to have a Karnofsky performance status (KPS) of ≥ 70 and
a life expectancy of ≥ 12 weeks at study entry.
Patients excluded had evidence of significant renal, hepatic or
bone marrow impairment (i.e. blood urea nitrogen and creatinine
<1.5 times the upper limit of normal; total and direct serum
bilirubin <1.5 times the upper limit of normal; absolute neutrophil
count [ANC] ≥ 1500/µ l; platelet count >100 000/µ l; and haemo-
globin >10 g/dl). Other exclusion criteria were >1 prior
chemotherapy regimen; history of previous chemotherapy with
single-agent PCB or dacarbazine; a regimen of chemotherapy
(excluding vincristine, nitrosourea or mitomycin C) within 4
weeks before study drug administration; vincristine within 2
weeks before study drug administration; nitrosourea or mitomycin
C within 6 weeks before study drug administration or a history of
PCB-induced rash; previous interstitial radiotherapy or stereo-
tactic radiosurgery; pregnancy; breast feeding. Women of child-
bearing potential had to be using adequate contraceptive
precautions. Patients experiencing toxicities from prior therapy,
those with medical conditions (HIV) and those with previous or
concurrent solid tumours at other sites (excluding basal cell carci-
nomas) were also excluded.
Study design and drug administration
The protocol was approved by the institutional review board or
independent ethics committee of each investigative facility and
conducted according to the Declaration of Helsinki and its amend-
ments. Patients gave informed consent before entering the study. A
blinded centralized review of neuropathology and neuroradiology
was performed. Eligibility was determined by blinded centralized
review of at least one histologic specimen from each surgical
procedure. GBM was classified according to the Burger and
Nelson system (Burger et al, 1985; McComb and Barger, 1985).
Monthly performance and clinical evaluation, neurologic exam-
inations, and quality-of-life measurements (questionnaire) were
done. Tumour was evaluated every 2 months with Gd-MRI or
contrast-enhanced CT scan. Image-based evidence of progression
is detectable before clinical deterioration and PFS was determined
by image-based progression on Gd-MRI scans, considering all
neurologic and clinical data indicative of disease progression.
Comprehensive evaluation of neurologic status was performed at
study visits comparing signs and symptoms from previous exami-
nation. Grading was definitely better (+2); possibly better (+1);
unchanged (0); possibly worse (–1); or definitely worse (–2).
Baseline Gd-MRI brain scan must have documented evaluable
(measurable or nonmeasurable) residual disease <14 days before
study drug administration. Patients were required to be on stable
doses of steroids for ≥ 7 days before the Gd-MRI scan. A baseline
Gd-MRI scan was performed within 72 h or 8 to 12 weeks after
surgical resection in patients undergoing surgery at first relapse.
TMZ dosing
TMZ was administered orally at a dosage of 150 mg/m2/day 
(750 mg/m2 total dose per cycle) on days 1–5 to fasting patients
who had received previous chemotherapy or at a dosage of 
200 mg/m2/day (1000 mg/m2 total dose per cycle) for patients who
had not received previous chemotherapy. Treatment cycles were
repeated every 28 days.
PCB dosing
PCB was administered orally at a starting dosage of 125 mg/
m2/day for 28 consecutive days (days 1–28) to those who had
received previous chemotherapy or at a dosage of 150 mg/m2/day
to patients who had not received previous chemotherapy.
Treatment cycles were repeated every 56 days.
Retreatment criteria
If the ANC was ≥ 2000/µ l and the platelet count was ≥ 125
000/µ l, repeat cycles could be administered to a maximum dose
of TMZ 200 mg/m2/day or PCB 220 mg/m2/day. In patients with
nadir ANC of 500–999 mm3 and nadir platelet count of
25,000–49,000 mm3, TMZ was reduced to the next lower dosage
level (150 mg/m2/day or 100 mg/m2/day), and PCB dose was
reduced by 25% from that of the previous cycle. In patients with
nadir ANC of <500 mm3 and nadir platelet count of <25 000
mm3, TMZ was reduced to the next lower dosage level, and PCB
was reduced by 50% from that of the previous cycle. For grades
3 and 4 nonhaematologic toxicity, TMZ was reduced by two
dosage levels, and PCB was reduced by 50% from that of the
previous cycle. Patients continued treatment until unacceptable
toxicity developed, disease progressed or 2-year treatment was
completed.
Other medications
Patients continued on the lowest steroid dosage necessary for
neurologic stability. Colony-stimulating factors were used only 
in cases of grade 4 neutropenia, when granulocyte colony-
stimulating factor was permitted.
Response determination
A complete response (CR) was the disappearance of all enhancing
tumour on consecutive MRI scans >1 month apart; discontinuation
of steroids (except for physiologic doses that may have been
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logic status. Partial response (PR) was defined as ≥ 50% reduction
in the sum of the products of the largest perpendicular diameters of
contrast enhancement for all measurable lesions or an assessment
of ‘definitely better’ for all nonmeasurable lesions on consecutive
MRI scans at least 1 month apart; stable steroid use for 7 days
before each scan (at dosage ≤ than had been administered at the
time of the previous scan); neurologic status stable or improved.
Progressive disease was a ≥ 25% increase in size of the product of
the largest perpendicular diameters of contrast enhancement for
any measurable lesions or an assessment of ‘definitely worse’ for
any nonmeasurable lesions or any new tumour on MRI scans. All
other situations were considered stable disease (SD).
Adverse drug-mediated events
Adverse events (AEs) were tabulated according to treatment
group. Treatment-emergent AEs were those beginning during or
within 30 days after the end of treatment or that began before and
worsened during treatment, regardless of any relationship to treat-
ment. If CTC criteria were not defined for a parameter, the
following grading scale was used: 0 = none; 1 = mild; 2 =
moderate; 3 = severe; 4 = life-threatening. Abnormal laboratory
values were recorded as AEs if they resulted in hospitalisation,
transfusion of blood products or discontinuation of therapy.
Worsening neurologic deficit was considered as a physical finding
associated with neurologic examination rather than an AE.
HRQL
The European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 [+3])
(Aaronson et al, 1993; Osoba et al, 1997) and the Brain Cancer
Module 20 (BCM20) (Osoba et al, 1996) questionnaires were used
to measure HRQL. Questionnaires were administered on day 1 of
cycle 1 and at every visit throughout the study. Seven HRQL
domains were selected a priori as most clinically relevant to
patients with brain cancer: role, social functioning and global
quality of life (from the EORTC-QLQ-C30 [+3]) and visual
disorder, motor dysfunction, communication deficit and drowsi-
ness (from the BCM20).
HRQL domains were scored according to EORTC instructions
(Fayers et al, 1995). Tests of statistical significance were not
applied. Meaning of changes in HRQL scores was addressed by
the method of Osoba et al (1998). A 10-unit change on a 0–100
scale was deemed significant if it lasted for at least 8 weeks
(Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al,
1998). Changes in HRQL scores from baseline were calculated for
patients at the same time points as HRQL completion. Proportions
of patients achieving an HRQL response (i.e. a 10-point improve-
ment from baseline in a domain for at least 2 consecutive months)
were calculated for each group.
Statistical methods
The primary objective was estimation of PFS at 6 months in the
intent-to-treat (ITT) population. With 100 patients per group,
assuming that the true 6-month PFS rate for TMZ was 20%, the
95% confidence interval (CI) would range from 12.2–27.8%. This
assured with confidence that the lower boundary of the 95% CI for
the 6-month PFS rate for TMZ would remain higher than 10%,
which was assumed to be the threshold of effectiveness.
A log-rank test used retrospectively determined whether mean-
ingful differences were detectable between the two groups. With
only progressive disease and death as events, PFS was measured
from the start date of treatment to an event date or the last evalua-
tion. Overall survival was measured from the start date of treat-
ment to the date of death or the last evaluation. The product-limit
method (Kaplan-Meier) was used to estimate PFS and overall
survival. A Cox regression model was used to assess influence of
baseline characteristics on the effect of treatment for PFS and
overall survival. Subgroup analyses for PFS and overall survival
were done according to prognostic variables in the Cox model.
RESULTS
Patient characteristics
Between January 5, 1995, and October 28, 1997, 225 patients were
randomised and became the ITT population. Five patients (TMZ, 
n = 2; PCB, n = 3) were randomized but not treated. Fifteen (13%)
TMZ patients and 31 (27%) PCB patients discontinued the study
for the following reasons other than disease progression: AEs
(TMZ, 3%; PCB, 10%); death (TMZ, 3%; PCB, 5%); noncompli-
ance with either dosing or visit schedule (TMZ, 0%; PCB, 4%);
failure to meet protocol eligibility (no treatment) (TMZ, 2%; PCB,
1%); completed treatment (TMZ, 2%; PCB, 1%) or did not wish to
continue (TMZ, 4%; PCB, 4%). Histologic review indicated that
tumours in 102/112 (91%) TMZ-treated patients and 108/113
(96%) PCB-treated patients were classified correctly as GBM or
gliosarcoma. Most patients excluded after reclassification were
judged to have anaplastic astrocytoma (7) or anaplastic oligoastro-
cytoma (3). Specimens for two patients were not reviewed, and
one sample was inadequate for review. Baseline and disease char-
acteristics were similar between treatment groups (P ≥ 0.19)
(Table 1). Median time from the end of radiation therapy to first
relapse and median time from initial diagnosis to first relapse were
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Table 1 Demographics of ITT population
TMZ PCB
(n = 112) (n = 113) P value
Age (years) 0.43a
Median 52 51
Range 21–76 21–74
Sex 0.48b
Male 77 (69%) 72 (64%)
Race 0.20c
White 106 (95%) 99 (88%)
Black 4 (4%) 7 (6%)
Other 2 (2%) 7 (6%)
KPS 0.19c
100 3 (3%) 10 (9%)
90 32 (29%) 30 (27%)
80 43 (38%) 34 (30%)
70 34 (30%) 38 (34%)
Not recorded 0 1 (1%)
Prior therapy
Surgical resection at initial 87% 91%
diagnosis
Adjuvant nitrosourea-based 65% 68%
chemotherapy
Time from initial diagnosis to first 7 8.4 0.02a
relapse (mo) (3.1–66) (2.2–92.3)
Time from end radiotherapy to first 4.6 5.8 0.03a
relapse (months) (0.6–63.6) (0.1–92.3)
aKruskal-Wallis test; bFisher’s exact test; cChi-square testshorter for TMZ-treated patients, but Cox regression analysis
revealed that these differences did not affect the overall inferences
of the study.
Six-month PFS
For TMZ patients, the 6-month PFS rate was 21% (95% CI,
13–29%), compared with 8% for PCB (95% CI, 3–14%; hazard
ratio, n = 1.54; P = 0.008). The 21% 6-month PFS for TMZ met
the protocol objective. Respective median PFS was 12.4 weeks for
TMZ patients and 8.32 weeks for PCB patients. The overall
progression-free interval also favoured TMZ (P = 0.0063) with a
hazard ratio of 1.47 (95% CI, 1.11–1.95%) (Figure 1). The differ-
ences in PFS rate appeared early and were maintained for several
months. Results in the subgroup with eligible histology were
similar to those reported for the ITT population. In the eligible
population, the 6-month PFS rate was 19% (95% CI, 11–27%),
compared with 9% for PCB (95% CI, 3–14%) The overall progres-
sion-free interval also favoured TMZ (P = 0.0063) in the eligible
population with a hazard ratio of 1.37. Analysis of data from time
of randomisation showed similar results, with a 6-month PFS rate
of 21% (95% CI, 13–29%), compared with 9% for PCB (95% CI,
4–15%; P = 0.016).
Overall survival
The median overall survival with TMZ was 1.5 months longer
than that with PCB, but this difference did not reach statistical
significance (P = 0.330). At 6 months, survival of the TMZ-
treated patients was 60% (95% CI, 51–70%) compared with 44%
in PCB-treated patients (95% CI, 35–53%; hazard ratio = 1.44; 
P = 0.019). The overall survival advantage for TMZ appeared at
4–6 months and persisted to at least 8 months (Figure 2). Analysis
from time of randomisation showed similar results in median
overall survival.
Prognostic factors and subgroup analyses
Multivariate analysis of baseline characteristics indicated that PFS
was related to baseline KPS (P = 0.0107), and overall survival was
related to baseline KPS (P = 0.0024) and age (P = 0.0359).
Patients were stratified by age (>50 or ≤ 50 years), time from initial
diagnosis to first relapse (>8 or ≤ 8 months), time from end of radi-
ation therapy at initial diagnosis to first relapse (>6 or ≤ 6 months)
and baseline KPS (>80 or ≤ 80). Analyses of these subgroups
demonstrated a consistent advantage for TMZ over PCB on PFS
and overall survival regardless of the subgroup; the hazard ratio
always exceeded 1.
Objective responses
According to the central reviewer’s assessment of objective
response, a PR occurred in 6/112 (5.4%) TMZ patients and in
6/113 (5.3%) PCB patients. SD occurred in 45/112 (40.2%) TMZ
patients and 31/113 (27.4%) PCB patients. Overall response rates
(PR + SD) of 51/112 (45.6%) in the TMZ group were significantly
higher than those of 37/113 (32.7%) in PCB group (P = 0.049).
HRQL assessment
HRQL scores were available at baseline and postbaseline for
179/220 (81.4%) treated patients. Regardless of the treatment,
HRQL scores were maintained at baseline levels prior to disease
progression but then decreased substantially at the time of disease
progression in six of the seven domains considered most clinically
relevant to patients (data not shown). Across all seven domains,
the proportions of patients achieving an HRQL response were
consistently higher for TMZ than they were for PCB (Figure 3).
Toxicity
Safety was assessed in the ITT population. Five patients (TMZ, 
n = 2; PCB, n = 3) who did not receive at least one dose of study
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6): 27–34medication were excluded from the analysis. A total of 110 TMZ-
treated patients received 484 cycles of TMZ, and 110 PCB-treated
patients received 167 cycles. Most PCB recipients were not treated
beyond cycle 1. By the end of week 12, 62/110 (56%) TMZ
patients and 36/110 (30%) PCB patients remained in the study,
others dropping out primarily for disease progression or toxicity.
TMZ and PCB were generally well tolerated, with similar inci-
dence of AEs in both groups (Table 2). The incidence of any AE
was 77% in the TMZ group and 76% in the PCB group. As shown
in Table 2, the incidence of grade 3 or 4 treatment-related AEs was
less with TMZ (18%) than with PCB (25%). Serious AEs were
reported for 169 patients (TMZ, n = 87; PCB, n = 82), primarily
for hospitalizations due to disease progression.
TMZ-associated myelosuppression was predictable and
reversible with no evidence of cumulative myelotoxicity. Nadir
platelet counts or ANCs typically occurred around days 21–28 and
recovered generally within 2 weeks. Most frequent AEs with TMZ
were nausea (42%), vomiting (35%) and fatigue (30%). Nausea
and vomiting were mild to moderate in most cases and were either
self-limiting or controlled with antiemetics. Most common CTC
grade 3 or 4 toxicities were thrombocytopenia (7%), neutropenia
(4%), fatigue (3%), vomiting (3%) and nausea (3%) in a small
number of patients in both treatment groups.
DISCUSSION
This large trial involving 255 patients demonstrates the efficacy
and safety of TMZ in the treatment of patients with recurrent
GBM. This confirms the results of several phase II studies of TMZ
in high-grade gliomas (Newlands et al, 1992, 1996; O’Reilly et al,
1993; Bower et al, 1997). Although the median time from initial
diagnosis to first relapse as well as the median time from the end
of radiation therapy to first relapse was shorter for TMZ recipients
than for PCB, a Cox regression analysis showed that these differ-
ences did not affect study outcome.
To ensure an objective index of efficacy, Gd-MRI and a manda-
tory central review were used to evaluate response. Because steroid
therapy can produce changes in imaging studies of central nervous
system malignancies, a stable dose of steroids before the initial Gd-
MRI scan was required; overall response criteria specified that use
of steroids should be stable for ≥ 7 days before the investigator’s
assessment. Patients adhered to mandated schedules of medical
imaging and neurologic examination, and protocol variations were
minimal. Oral PCB has demonstrated activity in relapsing malignant
gliomas. As the reference agent, PCB verified that objective end
points could be seen within the definition of the protocol and
permitted comparison of end points. The study size was designed to
demonstrate equivalent efficacy between the two drugs. Overall
response CPR+SD seen in response to PCB in this study (32.7%)
were similar to that found by Rodriguez et al 1989), but less than
that reported by Newton et al (1990). Comparisons between studies
are difficult because of differences in pathologic evaluation of
tumours and in the modalities used to measure disease progression.
PFS at 6 months, the primary end point of the protocol, was
significantly longer with TMZ than with PCB (21% vs. 8%);
overall PFS was also significantly longer for TMZ than for PCB.
The difference in PFS in favour of TMZ was observed as early as
1 month after randomisation and was maintained for several
months. Although the gain in PFS for TMZ patients did reflect
longer overall survival, it did not translate into a significant gain in
overall survival. PFS is a reliable and measurable end point when
appropriate imaging modalities are used for tumour evaluation and
is thus a clinically significant end point. Malignant gliomas are
progressive and ultimately fatal tumours; treatment maintaining
HRQL and useful survival for months is an important benefit. PFS
is also not influenced by subsequent therapies that may follow
progression.
Progressive, recurrent GBM causes deterioration of the patient’s
neurologic status and HRQL. A primary therapy goal in this incur-
able malignancy is symptom palliation and improvement or main-
tenance of HRQL. This study demonstrates that disease
progression is associated with HRQL deterioration and delaying
disease progression provides meaningful maintenance of HRQL to
patients with brain tumours. Some of the differences in HRQL
response between TMZ and PCB may have been related to the
dosing of TMZ over 5 days as compared with PCB, which was
dosed over a 28-day period.
Temozolomide has an acceptable safety profile in patients with
GBM. Since most PCB recipients were not treated beyond cycle 1,
patients received TMZ for a greater number of cycles. The number
of patients reporting at least one treatment-related AE was similar
for TMZ (77%) and PCB (76%), even though 90% of TMZ
patients received more than one cycle of treatment, compared with
only 33% of those treated with PCB. To provide balance, AEs
592 WKA Yung et al
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Table 2 Treatment-related AEs reported in ≥ 2% of patients in either
treatment group during days 1–56, safety population
Number (%) of patientsa
TMZ (n = 110) PCB (n = 110)
AEs All Grades 3/4 All Grades 3/4
Any 85 (77) 20 (18) 87 (76) 28 (25)
Nausea 42 (38) 3 (3) 37 (34) 3 (3)
Vomiting 35 (32) 3 (3) 30 (27) 5 (5)
Fatigue 30 (27) 3 (3) 16 (15) 2 (2)
Constipation 17 (15) 1 (1) 11 (10) 1 (1)
Anorexia 12 (11) 0 9 (8) 2 (2)
Headache 13 (12) 2 (2) 9 (8) 2 (2)
Rash 7 (6) 0 9 (8) 1 (1)
Thrombocytopenia 9 (8) 8 (7) 4 (4) 4 (4)
Neutropenia 4 (4) 4 (4) 4 (4) 3 (3)
Anemia 2 (2) 1 (1) 2 (2) 2 (2)
Leukopenia 2 (2) 1 (1) 0 0
Diarrhea 6 (5) 0 8 (7) 1 (1)
aHaematologic AEs are included regardless of percentageTemozolomide vs. procarbazine for relapse of glioblastoma 593
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were also examined for the first 56 days of treatment (i.e. one
complete cycle for PCB). During this period, more PCB patients
(21%) reported severe or life-threatening treatment-related AEs
than TMZ patients (15%). Only three TMZ patients dropped out
because of AEs compared with 11 PCB patients.
Although myelosuppression is a well-established dose-limiting
side effect of treatment with all alkylating agents, it occurred in
only a small number of TMZ recipients. When neutropenia and
thrombocytopenia developed, they usually occurred in the first
few treatment cycles, resolved with a one-level reduction in
dosage and were not cumulative.
This study demonstrates the safety and efficacy of TMZ in
recurrent GBM. TMZ is associated with an improvement in the
patient’s HRQL. The antitumour activity and predictability of
TMZ may prove valuable in patients with anaplastic astrocytomas
and in trials of patients with metastatic malignant melanoma and
other therapy-resistant tumours. Further benefit is anticipated on
combination of TMZ with agents such as the nitrosoureas, taxanes,
topoisomerase inhibitors and biologic-response modifiers and in
alternate dosing regimens (e.g. continuous-dosing studies).
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